CClinicalTrials.gg
Sign In
Status unknownNCT04333550Updated May 4, 2020

Application of Desferal to Treat COVID-19

A Phase 1/2 interventional study of Deferoxamine in COVID-19, sponsored by Kermanshah University of Medical Sciences. Status unknown at 1 site in Iran, Islamic Republic of. Open to participants aged 3 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-05-04.

Sponsored by Kermanshah University of Medical Sciences · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
3 Years to 99 Years
Sex
All
01

Study summary

In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

02

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19, Deferoxamine
03

In context

COVID-19

7,638 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 50 is below the median of 100 across 4,098 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Kermanshah University of Medical Sciences is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Clinical diagnosis of COVID-19 Disease,

Exclusion criteria

Exclusion Criteria:

Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental: Desferal addition to standard treatment

    Drug: Deferoxamine

  • Experimental
    Experimental: standard treatment

    Drug: Deferoxamine

Interventions

  • DrugDeferoxamine

    Intravenous infusion of Deferoxamine

06

What researchers measure

Primary outcomes

  1. Mortality rate

    All cause of death

    Time frame: up to 20 days

Secondary outcomes

  1. change in patients clinical manifestation

    Mild, Moderate or Severe

    Time frame: up to 20 days

  2. change in patients PaO2

    Time frame: up to 20 days

  3. Length of hospitalization

    days

    Time frame: up to 20 days

  4. C-reactive protein

    Time frame: up to 20 days

  5. lymphocyte count

    Time frame: up to 20 days

  6. length of intensive care unit stay

    Time frame: 1 to 20 days

07

Study locations

1 of 1 sites recruiting
  • Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
    Kermanshah, 083, Iran, Islamic Republic of
    • Yadollah Shakiba, MD, PhD · Contact
    Recruiting
08

References and documents

Publications

  • Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol. 2008 Jul;6(7):541-52. doi: 10.1038/nrmicro1930. PubMed 18552864 ↗
  • Nairz M, Haschka D, Demetz E, Weiss G. Iron at the interface of immunity and infection. Front Pharmacol. 2014 Jul 16;5:152. doi: 10.3389/fphar.2014.00152. eCollection 2014. PubMed 25076907 ↗
  • Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis. 2000 Feb;181(2):484-90. doi: 10.1086/315223. PubMed 10669330 ↗
  • Vlahakos D, Arkadopoulos N, Kostopanagiotou G, Siasiakou S, Kaklamanis L, Degiannis D, Demonakou M, Smyrniotis V. Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. Artif Organs. 2012 Apr;36(4):400-8. doi: 10.1111/j.1525-1594.2011.01385.x. Epub 2011 Dec 21. PubMed 22187937 ↗
  • Wang H, Li Z, Niu J, Xu Y, Ma L, Lu A, Wang X, Qian Z, Huang Z, Jin X, Leng Q, Wang J, Zhong J, Sun B, Meng G. Antiviral effects of ferric ammonium citrate. Cell Discov. 2018 Mar 27;4:14. doi: 10.1038/s41421-018-0013-6. eCollection 2018. PubMed 29619244 ↗
  • Cinatl J Jr, Cinatl J, Rabenau H, Gumbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res. 1994 Sep;25(1):73-7. doi: 10.1016/0166-3542(94)90095-7. PubMed 7811060 ↗
  • Visseren F, Verkerk MS, van der Bruggen T, Marx JJ, van Asbeck BS, Diepersloot RJ. Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest. 2002 Mar;32 Suppl 1:84-90. doi: 10.1046/j.1365-2362.2002.0320s1084.x. PubMed 11886437 ↗
  • Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses. 1995 Sep;11(9):1049-61. doi: 10.1089/aid.1995.11.1049. PubMed 8554902 ↗
  • Chang HC, Bayeva M, Taiwo B, Palella FJ Jr, Hope TJ, Ardehali H. Short communication: high cellular iron levels are associated with increased HIV infection and replication. AIDS Res Hum Retroviruses. 2015 Mar;31(3):305-12. doi: 10.1089/aid.2014.0169. Epub 2014 Oct 7. PubMed 25291189 ↗
  • Meyer D. Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload. Curr Pharm Des. 2006;12(16):1943-7. doi: 10.2174/138161206777442164. PubMed 16787239 ↗
  • Cinatl J, Scholz M, Weber B, Cinatl J, Rabenau H, Markus BH, Encke A, Doerr HW. Effects of desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells. Transpl Immunol. 1995 Dec;3(4):313-20. doi: 10.1016/0966-3274(95)80017-4. PubMed 8665150 ↗
  • Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G. Iron chelation therapy for malaria: a review. Pharmacol Ther. 1999 Jan;81(1):53-75. doi: 10.1016/s0163-7258(98)00037-0. PubMed 10051178 ↗
  • Weinberg GA. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994 May;38(5):997-1003. doi: 10.1128/AAC.38.5.997. PubMed 8067783 ↗
  • Paradkar PN, De Domenico I, Durchfort N, Zohn I, Kaplan J, Ward DM. Iron depletion limits intracellular bacterial growth in macrophages. Blood. 2008 Aug 1;112(3):866-74. doi: 10.1182/blood-2007-12-126854. Epub 2008 Mar 27. PubMed 18369153 ↗
  • Giannakopoulou E, Pardali V, Zoidis G. Metal-chelating agents against viruses and parasites. Future Med Chem. 2018 Jun 1;10(11):1283-1285. doi: 10.4155/fmc-2018-0100. Epub 2018 May 3. No abstract available. PubMed 29719970 ↗
  • Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, Backenstose A, Biemba G, Msiska R, Holmes L, McKinley E, et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med. 1992 Nov 19;327(21):1473-7. doi: 10.1056/NEJM199211193272101. PubMed 1406879 ↗
  • Duchemin JB, Paradkar PN. Iron availability affects West Nile virus infection in its mosquito vector. Virol J. 2017 Jun 5;14(1):103. doi: 10.1186/s12985-017-0770-0. PubMed 28583206 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04333550
Lead sponsor
Kermanshah University of Medical Sciences
Responsible party
Dr. Yadollah Shakiba (Dr. Yadollah Shakiba, MD, PhD, Kermanshah University of Medical Sciences) — Principal investigator
First posted
Apr 3, 2020
Start date
Apr 2020 (estimated)
Primary completion
Sep 2020 (estimated)
Completion
Mar 2021 (estimated)
Last update
May 4, 2020

Study contacts

Alireza Ghaffarieh, MD
Contact
alirezaghaffariyeh@hotmail.com
+1-608-698-7334
Yadollah Shakiba, MD, PhD
Contact
yshakiba@gmail.com
Yadollah Shakiba, MD, PhD
study director · Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Amir Kiani, PhD
principal investigator · Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

Kermanshah University of Medical Sciences

Start the discussion